Comparing Patient-Reported Outcomes Among Anti-TNF Experienced Patients With Ulcerative Colitis Initiating Vedolizumab Versus Tofacitinib.

Michael D Kappelman,Millie D Long,Xian Zhang,Feng-Chang Lin,Laura Weisbein,Wenli Chen,Jessica Burris,Jennifer E Dorand,Lauren E Parlett,Tara Fehlmann,Colleen M Brensinger,Kevin Haynes,Vinit Nair,Alan F Kaul,Angela Dobes,James D Lewis

Crohn's & colitis 360（2023）

引用 0|浏览15

暂无评分

摘要

Among anti-TNF experienced patients with UC, Pain Interference 4-10 months after treatment initiation was lower among tofacitinib users as compared with vedolizumab users. Many, but not all, secondary endpoints and subanalyses also favored tofacitinib. Future studies with larger sample sizes are needed to further evaluate these findings.

查看译文

关键词

Ulcerative colitis, comparative effectiveness research, patient-reported outcomes, tofacitinib, vedolizumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要